Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data

Autor: A. N. A. van der Horst-Schrivers, Ellen Kapiteijn, K R M Ferrier, M D Aydemirli, Juliette Zwaveling, Thera P. Links, Rolf H.H. Groenwold, K E Broekman, Petronella B. Ottevanger

Publikováno v: European Journal of Endocrinology, 182, 2, pp. 131-138
European Journal of Endocrinology, 182, 131-138
European Journal of Endocrinology, 182(2), 131-138. BIOSCIENTIFICA LTD

Objective The SELECT trial showed progression-free survival (PFS) benefit for lenvatinib for advanced radioiodine-refractory differentiated thyroid cancer (RAI-refractory or RR-DTC) patients, on which current clinical practice is based. We assessed w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8fffdedc9c6ce4b7c6c85c755def11
https://hdl.handle.net/2066/216644